Inactive Instrument

Small Pharma Inc.

Equities

DMT

CA8316641072

Biotechnology & Medical Research

Unilock Capital Corp. Reports Earnings Results for the Third Quarter Ended November 30, 2019

January 24, 2020 at 05:16 pm EST

Unilock Capital Corp. announced earnings results for the third quarter ended November 30, 2019. For the third quarter, the company announced net loss was CAD 44,622 compared to CAD 51,408 a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago. For the nine months, net loss was CAD 100,387 compared to CAD 71,641 a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.02 a year ago.

Latest news about Small Pharma Inc.

Small Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	Jan. 29	CI
Small Pharma Brief: Cybin Completed Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics	23-10-23	MT
Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).	23-10-22	CI
Small Pharma Brief: Shareholders overwhelmingly voted in favour of Cybin's acquisition	23-10-19	MT
Small Pharma Brief: Q2 FY24 Highlights Include Cash on hand as of August 31, 2023 of approximately C$7.7 million	23-10-19	MT
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	23-10-19	CI
Small Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	23-10-19	CI
Small Pharma Notes Positive Top-line Data from SPL026-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	23-09-26	MT
Small Pharma Brief: Reporting "Positive" Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	23-09-26	MT
Small Pharma Inc. Reports Positive Top-line Data from SPL026 (DMT-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	23-09-26	CI
Cybin Agrees to Acquire Small Pharma in All-Share Deal	23-08-28	MT
Transcript : Small Pharma Inc., Cybin Inc. - M&A Call	23-08-28
Small Pharma Inc.'s Equity Buyback announced on August 18, 2022, has expired with 1,788,000 shares, representing 0.55% for CAD 0.48 million.	23-08-17	CI
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	23-07-26	CI
Small Pharma Inc. Reports Earnings Results for the First Quarter Ended May 31, 2023	23-07-26	CI
Small Pharma Announces SPL028 R&D Strategy Update; Separately Announced Management Team Change	23-07-05	MT
Small Pharma Inc. Announces Management Changes	23-07-05	CI
Small Pharma Announces SPL028 R&D Strategy Update	23-07-05	CI
Small Pharma Inc. Announces Executive Team Change	23-07-05	CI
Small Pharma Brief: Notes "Operational Efficiencies Underway To Deliver Meaningful Runway Extension"	23-06-28	MT
Small Pharma Brief: For FY23, Adds Preliminary findings from SPL028 Phase I clinical trial support target drug profile	23-06-28	MT
Small Pharma Brief: For FY23, Says Multiple clinical milestones achieved including Frst proof-of-concept for DMT-based therapies from a blinded placebo-controlled study	23-06-28	MT
Small Pharma Brief: Says Cash on hand as of February 28, 2023 was approximately $18.5 million	23-06-28	MT
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	23-06-28	CI
Small Pharma Inc. Reports Earnings Results for the Full Year Ended February 28, 2023	23-06-28	CI

Chart Small Pharma Inc.

Duration

Period

More charts

Company Profile

Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of depression. It has a portfolio of clinical-stage dimethyltryptamine (DMT)-based assets, SPL026 and SPL028. It has a pipeline of proprietary preclinical assets. Its clinical-stage program, SPL026, a first-generation DMT molecule, has shown proof-of-concept for the potential treatment of MDD. In a Phase IIa study, IV SPL026 demonstrated a rapid and durable antidepressant effect, as well as a favorable safety and tolerability profile. Small Pharma is also advancing SPL028, a second-generation injectable deuterated DMT molecule, in a Phase I trial.

Sector

Biotechnology & Medical Research

Calendar

2024-07-25 - Q1 2025 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+34.35%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research